Abiomed

Abiomed, Inc. is a leading medical technology company based in Danvers, Massachusetts, specializing in cardiac support and heart recovery. Founded in 1981, Abiomed initially focused on developing the AbioCor, the first fully implantable artificial heart, which received FDA approval in 2006. The company has since shifted its mission to emphasize innovative ventricular assist devices (VADs) that support and restore cardiac function. The flagship product line, the Impella® family of percutaneous ventricular assist devices, includes models like Impella 2.5, Impella CP, Impella 5.5, and Impella BTR. These devices are designed to assist the heart's pumping function during high-risk procedures and emergency cardiac care, allowing the heart to rest and heal. Abiomed also offers the BVS5000 cardiac support system, used to support patients post-heart surgery or during heart failure episodes. The company serves hospitals, cardiac surgery centers, and catheterization labs globally, improving outcomes for patients with heart failure or cardiogenic shock. In 2022, Abiomed was acquired by Johnson & Johnson, enhancing its position in the cardiovascular device market.

• Employees 2100
• Founded 1981
• Annual Revenue $1031753000
• Total Funding $48055514